

**MTN007: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and
Acceptability Study of Tenofovir 1% Gel
Visit Adherence: Completion of Procedures during Follow-Up by Site*
Analysis Date: 07SEP11**

	Total	Pittsburgh, PA	Birmingham, AL	Boston, MA
Participant-Visits where Rectal Exams are Required and Expected	127	42	44	41
Perianal Visual Examination				
Not Completed	3(2%)	0	1(2%)	2(5%)
Completed	124(98%)	42(100%)	43(98%)	39(95%)
Digital Rectal Examination				
Not Completed	4(3%)	0	2(5%)	2(5%)
Completed	123(97%)	42(100%)	42(95%)	39(95%)
Participant-Visits where Anoscopy and Sigmoidoscopy are Required and Expected	126	42	43	41
Anoscopy Performed				
Not Completed	2(2%)	0	0	2(5%)
Completed	124(98%)	42(100%)	43(100%)	39(95%)
Sigmoidoscopy Performed				
Not Completed	2(2%)	0	0	2(5%)
Completed	124(98%)	42(100%)	43(100%)	39(95%)
Participant-Visits where Pregnancy Tests are Required and Expected	57	9	39	9
Completed	57(100%)	9(100%)	39(100%)	9(100%)
Participant-Visits where Laboratory Tests are Required and Expected	64	21	22	21
Completed	62(97%)	21(100%)	22(100%)	19(90%)
Partially Completed	1(2%)	0	0	1(5%)
Not Completed	1(2%)	0	0	1(5%)
Participant-Visits where Specimen Storage is Required and Expected	126	42	43	41
Completed	101(80%)	32(76%)	42(98%)	27(66%)
Partially Completed	23(18%)	10(24%)	1(2%)	12(29%)
Not Completed	2(2%)	0	0	2(5%)
Participant-Visits where Completion of the CASI Product Acceptability Questionnaire is Required and Expected	48	16	17	15
Not Completed	1(2%)	0	1(6%)	0
Completed	47(98%)	16(100%)	16(94%)	15(100%)

*Includes only Treatment 1, Treatment 2, Final Clinic, Early Termination and Interim (pregnancy tests only) visits where appropriate.

DATASETS: SCHARP (zpan)-/trials/mtn/p007/reporting/progress/adherence/code/visit_adherence_adata.sas

SOURCE: /trials/mtn/p007/reporting/progress/adherence/code/visit_adherence_table.sas

OUTPUT: /trials/mtn/p007/reporting/progress/adherence/code/MTN007_visit_adherence_table.pdf SAS Version 9.2 (07SEP11/15:45)